Assess whether RWE can replace or only supplement an RCT (d88520)

Situation

After an inspector asking for batch records you cannot produce this week, disproportionate reporting signal workbook is what CMC change-control owner can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with RWE can replace versus Only supplement an RCT on this Pharmacovigilance file.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled Pharmacovigilance process in a mid-size sponsor after a complete response letter, given disproportionate reporting signal workbook.
• An inspector asking for batch records you cannot produce this week is the event in disproportionate reporting signal workbook that forces RWE can replace for CMC change-control owner under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a Pharmacovigilance program failure.
• Disproportionate reporting signal workbook cannot decide RWE can replace or yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against an inspector asking for batch records you cannot produce this week and write the one fact that would move RWE can replace or for CMC change-control owner.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week cannot support RWE can replace versus Only supplement an RCT on this Pharma & Life Sciences Pharmacovigilance close, CMC change-control owner must state the unresolved clinical or safety evidence requirement explicitly.